SHR-4849 + SHR-1316 + SHR-8068 + BP102 + carboplatin + cisplatin

This is a **combination regimen** consisting of six investigational and established antineoplastic agents: SHR-4849, SHR-1316, SHR-8068, BP102, carboplatin, and cisplatin. SHR-4849 is a novel antibody-drug conjugate (ADC) targeting **delta-like ligand 3 (DLL3)** with a **topoisomerase I (Topo-I) inhibitor** payload, currently in phase 1/2 clinical trials for advanced solid tumors including small cell lung cancer (SCLC) and neuroendocrine tumors (NETs)[1][3][4][7]. SHR-1316, SHR-8068, and BP102 are investigational compounds whose specific mechanisms are not disclosed in the provided context. Carboplatin and cisplatin are platinum-based chemotherapy agents widely used in oncology for their DNA crosslinking and cytotoxic effects. The combination aims to leverage targeted ADC therapy with established cytotoxic agents for enhanced antitumor efficacy in refractory or advanced solid malignancies.